## AZN: Astrazeneca PLC - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%); PEG 1.03 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($88.27)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Rexford Capital Inc. Invests $948,000 in AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251214T111016 | Bullish | Relevance: 100%
- Rexford Capital Inc. initiated a new position in AstraZeneca PLC (NASDAQ:AZN) during the second quarter, purchasing 13,566 shares valued at approximately $948,000. Several other institutional investors also significantly increased their holdings in AstraZeneca. The company recently exceeded quarterly earnings expectations and holds a "Moderate Buy" consensus analyst rating with a target price of $95.75.

**2. AstraZeneca's Enhertu and Genentech's Perjeta combo gains breast cancer approval**
- Source: Seeking Alpha | 20251215T220918 | Bullish | Relevance: 100%
- The U.S. FDA has approved a combination therapy of AstraZeneca/Daiichi Sankyo's Enhertu and Roche-owned Genentech's Perjeta for the first-line treatment of HER2-positive breast cancer. This approval is based on phase 3 data indicating that the combination significantly reduced disease progression or death.

**3. Holocene Advisors LP Sells 124,752 Shares of AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251214T131016 | Somewhat-Bullish | Relevance: 100%
- Holocene Advisors LP has reduced its stake in AstraZeneca PLC by selling 124,752 shares, bringing its total holdings to 4,321,629 shares valued at approximately $302 million. This move makes AstraZeneca the 26th-largest holding in the fund's portfolio, representing about 0.7% of its total assets. The company recently exceeded quarterly expectations with an EPS of $1.19 and revenue of $15.19 billion, while analysts currently rate AZN as a "Moderate Buy" with a target price of $95.75.

**4. AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment**
- Source: Reuters | 20251216T010918 | Bullish | Relevance: 100%
- The U.S. Food and Drug Administration (FDA) has approved Enhertu, a breast cancer drug from AstraZeneca and Daiichi Sankyo, for first-line treatment in combination with Roche's Perjeta. This expanded approval targets adults with advanced HER2-positive breast cancer, based on study results showing a significant extension in progression-free survival. The decision moves Enhertu beyond its initial third-line treatment approval in 2019.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $283.2B |
| Beta | 0.17 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 17.7 |
| Current P/E | 19.9 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.3% to 2.1% (+2.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 1.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.12% (CS: 67) | Neutral |
| RSI_14 | 57.7 | Neutral |
| MACD Histogram | -0.27 | Bearish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 1.049x | Above |
| vs SMA200 | 1.187x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $91.35
- **Stop Loss:** $88.27 (3.4% risk)
- **Target:** $94.43 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 324
- **Position Value:** $29,597.40
- **Portfolio %:** 29.60%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*